Literature DB >> 20697348

Analysis of the genome to personalize therapy for melanoma.

M A Davies1, Y Samuels.   

Abstract

The treatment of cancer is being revolutionized by an improved understanding of the genetic events that occur in tumors. Advances in the understanding of the prevalence and patterns of mutations in melanoma have recently led to impressive results in trials of personalized, targeted therapies for this disease. In this review, we will discuss the molecular targets that have been validated clinically, additional genetic events that are candidates for future trials, and the challenges that remain to improve outcomes further in this aggressive disease.

Entities:  

Mesh：

Substances：

Year:  2010        PMID： 20697348      PMCID： PMC3169242          DOI： 10.1038/onc.2010.323

Source DB:  PubMed          Journal:  Oncogene        ISSN： 0950-9232            Impact factor:   9.867


  119 in total

1.  Mutation and allelic loss of the PTEN/MMAC1 gene in primary and metastatic melanoma biopsies.

Authors:  A Birck; V Ahrenkiel; J Zeuthen; K Hou-Jensen; P Guldberg
Journal:  J Invest Dermatol       Date:  2000-02       Impact factor: 8.551

Review 2.  Post-translational modifications and regulation of the RAS superfamily of GTPases as anticancer targets.

Authors:  Panagiotis A Konstantinopoulos; Michalis V Karamouzis; Athanasios G Papavassiliou
Journal:  Nat Rev Drug Discov       Date:  2007-07       Impact factor: 84.694

3.  Detection of high incidence of K-ras oncogenes during human colon tumorigenesis.

Authors:  K Forrester; C Almoguera; K Han; W E Grizzle; M Perucho
Journal:  Nature       Date:  1987 May 28-Jun 3       Impact factor: 49.962

4.  Examination of mutations in BRAF, NRAS, and PTEN in primary cutaneous melanoma.

Authors:  Vikas K Goel; Alexander J F Lazar; Carla L Warneke; Mark S Redston; Frank G Haluska
Journal:  J Invest Dermatol       Date:  2006-01       Impact factor: 8.551

Review 5.  Genetic alterations in signaling pathways in melanoma.

Authors:  Frank G Haluska; Hensin Tsao; Helen Wu; Frank S Haluska; Alexander Lazar; Vikas Goel
Journal:  Clin Cancer Res       Date:  2006-04-01       Impact factor: 12.531

Review 6.  Ultraviolet radiation and melanoma: a systematic review and analysis of reported sequence variants.

Authors:  Thomas Hocker; Hensin Tsao
Journal:  Hum Mutat       Date:  2007-06       Impact factor: 4.878

7.  A comprehensive catalogue of somatic mutations from a human cancer genome.

Authors:  Erin D Pleasance; R Keira Cheetham; Philip J Stephens; David J McBride; Sean J Humphray; Chris D Greenman; Ignacio Varela; Meng-Lay Lin; Gonzalo R Ordóñez; Graham R Bignell; Kai Ye; Julie Alipaz; Markus J Bauer; David Beare; Adam Butler; Richard J Carter; Lina Chen; Anthony J Cox; Sarah Edkins; Paula I Kokko-Gonzales; Niall A Gormley; Russell J Grocock; Christian D Haudenschild; Matthew M Hims; Terena James; Mingming Jia; Zoya Kingsbury; Catherine Leroy; John Marshall; Andrew Menzies; Laura J Mudie; Zemin Ning; Tom Royce; Ole B Schulz-Trieglaff; Anastassia Spiridou; Lucy A Stebbings; Lukasz Szajkowski; Jon Teague; David Williamson; Lynda Chin; Mark T Ross; Peter J Campbell; David R Bentley; P Andrew Futreal; Michael R Stratton
Journal:  Nature       Date:  2009-12-16       Impact factor: 49.962

8.  Mutations of the BRAF gene in benign and malignant melanocytic lesions.

Authors:  Amir S Yazdi; Gabriele Palmedo; Michael J Flaig; Ursula Puchta; Andrea Reckwerth; Arno Rütten; Thomas Mentzel; Heino Hügel; Markus Hantschke; Monika-Hildegard Schmid-Wendtner; Heinz Kutzner; Christian A Sander
Journal:  J Invest Dermatol       Date:  2003-11       Impact factor: 8.551

9.  The lipid phosphatase activity of PTEN is critical for its tumor supressor function.

Authors:  M P Myers; I Pass; I H Batty; J Van der Kaay; J P Stolarov; B A Hemmings; M H Wigler; C P Downes; N K Tonks
Journal:  Proc Natl Acad Sci U S A       Date:  1998-11-10       Impact factor: 11.205

10.  Lack of clinical efficacy of imatinib in metastatic melanoma.

Authors:  S Ugurel; R Hildenbrand; A Zimpfer; P La Rosée; P Paschka; A Sucker; P Keikavoussi; J C Becker; W Rittgen; A Hochhaus; D Schadendorf
Journal:  Br J Cancer       Date:  2005-04-25       Impact factor: 7.640
View more
  51 in total

Review 1.  Applications of targeted gene capture and next-generation sequencing technologies in studies of human deafness and other genetic disabilities.

Authors:  Xi Lin; Wenxue Tang; Shoeb Ahmad; Jingqiao Lu; Candice C Colby; Jason Zhu; Qing Yu
Journal:  Hear Res       Date:  2012-01-14       Impact factor: 3.208

2.  Activities of multiple cancer-related pathways are associated with BRAF mutation and predict the resistance to BRAF/MEK inhibitors in melanoma cells.

Authors:  Dingxie Liu; Xuan Liu; Mingzhao Xing
Journal:  Cell Cycle       Date:  2013-10-29       Impact factor: 4.534

3.  Genotyping of cutaneous melanoma.

Authors:  Isabella C Glitza; Michael A Davies
Journal:  Chin Clin Oncol       Date:  2014-09

Review 4.  Adoptive immunotherapy for cancer: harnessing the T cell response.

Authors:  Nicholas P Restifo; Mark E Dudley; Steven A Rosenberg
Journal:  Nat Rev Immunol       Date:  2012-03-22       Impact factor: 53.106

5.  Epigenetic genes regulated by the BRAFV600E signaling are associated with alterations in the methylation and expression of tumor suppressor genes and patient survival in melanoma.

Authors:  Dingxie Liu; Xuan Liu; Mingzhao Xing
Journal:  Biochem Biophys Res Commun       Date:  2012-07-17       Impact factor: 3.575

Review 6.  The molecular genetics of eyelid tumors: recent advances and future directions.

Authors:  Tatyana Milman; Steven A McCormick
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2012-12-30       Impact factor: 3.117

7.  Correlation of NRAS mutations with clinical response to high-dose IL-2 in patients with advanced melanoma.

Authors:  Richard W Joseph; Ryan J Sullivan; Robyn Harrell; Katherine Stemke-Hale; David Panka; George Manoukian; Andrew Percy; Roland L Bassett; Chaan S Ng; Laszlo Radvanyi; Patrick Hwu; Michael B Atkins; Michael A Davies
Journal:  J Immunother       Date:  2012-01       Impact factor: 4.456

Review 8.  Exploiting the curative potential of adoptive T-cell therapy for cancer.

Authors:  Christian S Hinrichs; Steven A Rosenberg
Journal:  Immunol Rev       Date:  2014-01       Impact factor: 12.988

9.  The lncRNA RMEL3 protects immortalized cells from serum withdrawal-induced growth arrest and promotes melanoma cell proliferation and tumor growth.

Authors:  Cibele Cardoso; Rodolfo B Serafim; Akinori Kawakami; Cristiano Gonçalves Pereira; Jason Roszik; Valeria Valente; Vinicius L Vazquez; David E Fisher; Enilza M Espreafico
Journal:  Pigment Cell Melanoma Res       Date:  2018-12-16       Impact factor: 4.693

10.  BRAF inhibition increases tumor infiltration by T cells and enhances the antitumor activity of adoptive immunotherapy in mice.

Authors:  Chengwen Liu; Weiyi Peng; Chunyu Xu; Yanyan Lou; Minying Zhang; Jennifer A Wargo; Jie Qing Chen; Haiyan S Li; Stephanie S Watowich; Yan Yang; Dennie Tompers Frederick; Zachary A Cooper; Rina M Mbofung; Mayra Whittington; Keith T Flaherty; Scott E Woodman; Michael A Davies; Laszlo G Radvanyi; Willem W Overwijk; Gregory Lizée; Patrick Hwu
Journal:  Clin Cancer Res       Date:  2012-11-30       Impact factor: 12.531
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.